Dazomet is a broad-spectrum soil fumigant used to control various plant pathogens, including fungi, bacteria, nematodes, and weeds. It is synthesized by reacting methyl isothiocyanate with formaldehyde and ammonia. Dazomet decomposes in the soil to produce methyl isothiocyanate, the active fumigant, which is a volatile compound that readily penetrates soil pores. The fumigant action of dazomet is believed to be primarily due to its ability to disrupt the cellular structure of target organisms, leading to their death. Dazomet is particularly effective against soil-borne pathogens that cause diseases such as damping-off, root rot, and wilt. It is also used to control plant-parasitic nematodes, which can damage crops by feeding on roots. Dazomet is widely used in agriculture, horticulture, and forestry to improve soil health and enhance crop yields. Due to its broad-spectrum activity and effectiveness, dazomet is a valuable tool for controlling soil-borne pests and diseases. However, its use is subject to regulatory restrictions in some countries due to potential environmental concerns associated with its decomposition products. Ongoing research is exploring alternative soil fumigants with reduced environmental impact and improved efficacy against specific pests and pathogens.'
dazomet: fumigant for poultry litter & eggs to control salmonella; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
dazomet : A dithiocarbamic ester that is 1,3,5-thiadiazinane with a thione moiety at position 2 and in which the hydrogens attached to the nitrogens are replaced by methyl groups. A fungicide, herbicide and nematicide, it is used prior to sowing or planting for the control of soil fungi, nematodes, bacteria and germinating weeds, and as fumigant for poultry litter and eggs to control Salmonella. It is a non-ozone-depleting alternative to methyl bromide. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 10788 |
| CHEMBL ID | 1407826 |
| CHEBI ID | 75212 |
| SCHEMBL ID | 21382 |
| MeSH ID | M0060205 |
| Synonym |
|---|
| AC-12680 |
| 4-27-00-07436 (beilstein handbook reference) |
| 3,5-dimetil-peridro-1,3,5-tiadiazin-2-tione |
| unii-s7419cg4w5 |
| 3,5-dimethylperhydro-1,3,5-thiadiazin-2-thion |
| s7419cg4w5 , |
| MLS000104430-02 |
| 3,3,5-thiadiazine |
| mico-fume |
| 3,3,5-2h-tetrahydrothiadiazine-2-thione |
| 533-74-4 |
| nefusan |
| basamid g |
| 2h-1,5-thiadiazine-2-thione, tetrahydro-3,5-dimethyl- |
| crag 974 |
| 3,3,5-2h-thioadiazine-2-thione |
| micofume |
| 2-thio-3,3,5-thiadiazine |
| dimethylformocarbothialdine |
| n 521 |
| 3,2,3,5-tetrahydro-1,3,5-thiadiazinethione-2 |
| thiazon |
| mylon |
| crag 85w |
| crag nemacide |
| crag fungicide 974 |
| fennosan b 100 |
| basamid |
| stauffer n 521 |
| tetrahydro-3,3,5-thiadiazine-2-thione |
| basamid p |
| 3,3,5-thiadiazine-2-thione |
| 3,3,5-2h-thiadiazine-2-thione |
| carbothialdin |
| 3,3,5-tiadiazin-2-tione |
| nalcon 243 |
| tiazon |
| mylone |
| nsc4737 |
| prezervit |
| tetrahydro-2h-3,3,5-thiadiazine-2-thione |
| nsc-4737 |
| 3,3,5-thiadiazin-2-thion |
| thiadiazin (pesticide) |
| dmtt |
| mylone 85 |
| dazomet |
| wln: t6nys entj a1 bus e1 |
| ucc 974 |
| thiazone |
| basamide |
| basamid-puder |
| 2h-1,3,5-thiadiazine-2-thione, tetrahydro-3,5-dimethyl- |
| 3,5-dimethyl-1,3,5-thiadiazinane-2-thione |
| NCGC00080412-02 |
| 3,5-dimethyl-1,2,3,5-tetrahydro-1,3,5-thiadiazinethione-2 |
| 3,5-dimethyltetrahydro-1,3,5-thiadiazine-2-thione |
| salvo [czech] |
| dazomet [bsi:iso] |
| epa pesticide chemical code 035602 |
| nsc 4737 |
| tetrahydro-2h-3,5-dimethyl-1,3,5-thiadiazine-2-thione |
| dazomet-powder basf |
| troysan 142 |
| 3,5-dimethyl-1,3,5-(2h)-tetrahydrothiadiazine-2-thione |
| basamid-granular |
| 3,5-dimetil-peridro-1,3,5-tiadiazin-2-tione [italian] |
| basamid - purder |
| d 35 |
| hsdb 1642 |
| 3,5-dimethyltetrahydro-1,3,5-2h-thiadiazine-2-thione |
| tetrahydro-3,5-dimethyl-2h-1,3,5-thiadiazine-2-thione |
| einecs 208-576-7 |
| 2-thio-3,5-dimethyltetrahydro-1,3,5-thiadiazine |
| 3,5-dimethyltetrahydro-2h-1,3,5-thiadiazine-2-thione |
| 3,5-dimethylperhydro-1,3,5-thiadiazin-2-thion [czech, german] |
| caswell no. 840 |
| brn 0116039 |
| 3,5-dimethyl-2-thionotetrahydro-1,3,5-thiadiazine |
| mylon [czech] |
| MLS000104430 |
| smr000054365 |
| MIXCOM1_000020 |
| MAYBRIDGE1_000020 |
| SR-01000641863-1 |
| 2h-1,3,5-thiadiazine-2-thione, tetrahydro-3,5-dimethyl |
| NCGC00080412-01 |
| NCGC00080412-04 |
| NCGC00080412-03 |
| C18457 |
| tox21_201236 |
| dtxsid7024902 , |
| NCGC00258788-01 |
| dtxcid004902 |
| NCGC00254892-01 |
| cas-533-74-4 |
| tox21_300990 |
| A829551 |
| AKOS006230484 |
| CHEBI:75212 , |
| dazoberg |
| CCG-2038 |
| HMS2277P17 |
| FT-0603127 |
| dazomet [hsdb] |
| dazomet [mi] |
| dazomet [iso] |
| SCHEMBL21382 |
| W-105744 |
| 3,5-dimethyl-1,3,5-2h-tetrahydrothiadiazine-2-thione |
| 3,5-dimethyl tetrahydro-2-h,1,3,5-thiadiazone-2-thione |
| 3,5-dimethyltetrahydro-1,3,5-2h-thioadiazine-2-thione |
| amerstat 233 (salt/mix) |
| tetrahydro-3,5-dimethyl-2h-1,3,5-thiodiazin-2-thione |
| 3,5-dimethyl-tetrahydro-1,3,5-thiadiazine-2-thione |
| 3,5-dimethyl-1,3,5-thiadiazinane-2-thione # |
| CHEMBL1407826 |
| dazomet, pestanal(r), analytical standard |
| mfcd00023809 |
| AS-15262 |
| Q424814 |
| ml064 |
Dazomet is a soil fumigant effective against germinating weed seeds, nematodes, soil fungi, and soil insects.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Dazomet is a soil fumigant effective against germinating weed seeds, nematodes, soil fungi, and soil insects. " | ( In vivo studies on genotoxicity of a soil fumigant, dazomet. Bolognesi, C; Landini, E; Munnia, A; Parodi, S; Peluso, M, 1998) | 1.99 |
Pre-treatment with Dazomet significantly enhanced the biocontrol effects of the fungus.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Pre-treatment with Dazomet significantly enhanced the biocontrol effects of the fungus." | ( Pre-treatment with Dazomet enhances the biocontrol efficacy of purpureocillium lilacinum to Meloidogyne incognita. Li, S; Lv, B; Nie, H; Sun, M; Zhong, Z, 2023) | 1.56 |
| "Pre-treatment with Dazomet greatly increased the biocontrol efficacy of P. " | ( Pre-treatment with Dazomet enhances the biocontrol efficacy of purpureocillium lilacinum to Meloidogyne incognita. Li, S; Lv, B; Nie, H; Sun, M; Zhong, Z, 2023) | 1.57 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Although fungicides could be the best solution in combating fungal infections in crops, however, the phytotoxic level of fungicides to the crops should be tested first to ensure that it is safe for the crops." | ( Phytotoxicity of chitosan-based agronanofungicides in the vegetative growth of oil palm seedling. Daim, LDJ; Fakurazi, S; Hilmi, NHZ; Hussein, MZ; Idris, AS; Maluin, FN; Yusof, NA, 2020) | 0.56 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " In this study, we conducted field experiments to investigate the practical effects of tilling the soil down to a depth of 40 cm (40dp) in combination with dazomet (D) soil fumigation and/or the application of a bio-organic fertilizer (B) on chrysanthemum growth, with a focus on the potential mechanisms underlying the responses of the soil microbiome." | ( Deep tillage combined with biofertilizer following soil fumigation improved chrysanthemum growth by regulating the soil microbiome. Chen, F; Chen, H; Chen, S; Fang, W; Guan, Z; Jiang, J; Zhang, K; Zhao, J; Zhao, S, 2020) | 0.76 |
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thiazon at the dosage of 200 g/m2 produces a total ovicidal effect on the eggs of Ascaris and Trichurus, laid on soil surface at 12-30-days exposition; at the depth of 5 cm the number of Ascaris eggs reduced by 40-85% and those of Trichurus--by 29-81%, whereas in the intact soil 100% eggs' viability preserved." | ( [The effect of thiazon on helminth eggs in soil]. Babaeva, RI, ) | 0.13 |
| Role | Description |
|---|---|
| herbicide | A substance used to destroy plant pests. |
| nematicide | A substance used to destroy pests of the phylum Nematoda (roundworms). |
| antibacterial agent | A substance (or active part thereof) that kills or slows the growth of bacteria. |
| antifungal agrochemical | Any substance used in acriculture, horticulture, forestry, etc. for its fungicidal properties. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| dithiocarbamic ester | Any ester derived from a member of the class of dithiocarbamic acids by formal replacement of the -SH group by -SR, where R is an organyl group. |
| thiadiazinane | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 10.0000 | 0.0251 | 20.2376 | 39.8107 | AID886 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 10.0000 | 0.0251 | 20.2376 | 39.8107 | AID886 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 17.7828 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| acetylcholinesterase | Homo sapiens (human) | Potency | 88.9212 | 0.0025 | 41.7960 | 15,848.9004 | AID1347398 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 44.6684 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 7.9038 | 3.1890 | 29.8841 | 59.4836 | AID1224846 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 1.7418 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
| TDP1 protein | Homo sapiens (human) | Potency | 5.5620 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 1.7511 | 0.0007 | 14.5928 | 83.7951 | AID1259368; AID1259369; AID1259392 |
| AR protein | Homo sapiens (human) | Potency | 6.9825 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID588516; AID743035; AID743042; AID743054; AID743063 |
| Smad3 | Homo sapiens (human) | Potency | 7.9433 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
| apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 17.7828 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
| caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 34.3004 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 39.8107 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 16.3474 | 0.0006 | 57.9133 | 22,387.1992 | AID1259377; AID1259378 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 7.3593 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
| progesterone receptor | Homo sapiens (human) | Potency | 32.0740 | 0.0004 | 17.9460 | 75.1148 | AID1346784; AID1346795 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 7.6921 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 22.6291 | 0.0002 | 14.3764 | 60.0339 | AID588532; AID720691; AID720692; AID720719 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 8.1683 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159553; AID1159555 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 16.8191 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531; AID588544 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 18.0007 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 8.2035 | 0.3758 | 27.4851 | 61.6524 | AID743217 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 25.9801 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982; AID720659 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 17.4528 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248; AID743069; AID743078; AID743079; AID743080; AID743091 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 7.1254 | 0.0010 | 24.5048 | 61.6448 | AID588535; AID743212; AID743215; AID743227 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 6.8803 | 0.0010 | 19.4141 | 70.9645 | AID743094 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 6.5456 | 0.0237 | 23.2282 | 63.5986 | AID743222; AID743241 |
| caspase-3 | Homo sapiens (human) | Potency | 34.3004 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 39.8107 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 4.3382 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 8.4138 | 0.1434 | 27.6121 | 59.8106 | AID1159516; AID1159519 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 8.7336 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 3.0364 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 10.6731 | 0.0391 | 47.5451 | 146.8240 | AID1224845; AID1224896 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 3.9517 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 1.0070 | 0.0420 | 27.3789 | 61.6448 | AID743210; AID743228 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 26.6795 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 25.3936 | 0.0006 | 27.2152 | 1,122.0200 | AID651741; AID720636; AID743202; AID743219 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 6.4918 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
| geminin | Homo sapiens (human) | Potency | 16.3601 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 15.3961 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 5.4316 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 15.3961 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 2.8184 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 50.1187 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 15.8489 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (1.96) | 18.7374 |
| 1990's | 4 (7.84) | 18.2507 |
| 2000's | 7 (13.73) | 29.6817 |
| 2010's | 25 (49.02) | 24.3611 |
| 2020's | 14 (27.45) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (52.88) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (1.82%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 3 (5.45%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 51 (92.73%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||